• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]


Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
     
BMY [ Bristol-Myers Squibb Company ]
Last Trade 59.14 Date 7/2/2020
Change % 0.28 % Price Change 0.16
Open 59.3 52 Week High 68.34
High 59.64 52 Week Low 42.48
Low 58.75 Type stock
Volume 11366050 Average Volume 14680788
Prev Close 58.98 Stock Exchange NYSE
Bid 58.9 Ask 59.39
Bid Size 2 Ask Size 1
1st Yr Estimated EPS Growth 3.2522 2nd Yr Estimated EPS Growth 0.2333
2 Years Forward Earning Yield 0.1281 2 Years Forward PE Ratio 7.8037
2 Years EV/Forward EBIT 7.839 2 Years EV/Forward EBITDA 7.8166
Book Value per Share 22.0583 Book Value Yield 0.373
Buy Back Yield 0.0552 CAPE Ratio 33.2246
Cash Return 0.0642 Cash Flow per Share 5.6613
Cash Flow Yield 0.0957 Dividend Rate 1.8
Dividend Yield 2.98 5 Year Dividend Yield 0.0274
Earning Yield 0.0107 EV/EBIT 44.4812
EV/EBITDA 21.1225 EV / Free Cash Flow 16.7152
EV / Forward EBIT 9.3513 EV / Forward EBITDA 10.5478
EV / Forward Revenue 3.8676 EV / Pre Tax Income 60.5585
EV / Revenue 5.2578 EV / Total Asset 1.261
Expected Dividend Growth Rate 0.0227 Free Cash Flow per Share 5.2232
Free Caash Flow Ratio 11.322584 Free Cash Flow Yield 0.0883
Forward Calculation Style Annual Forward Dividend Yield 0.0304
Forward Earning Yield 0.1039 Forward PE Ratio 9.6246
Forward Return on Asset 0.1075 Forward Return on Equity 0.2786
Normalized PE Ratio 11.137476 Payout Ratio 2.7302
PB Ratio 2.681082 PB Ratio 10 Year Growth -7.88E-4
PB Ratio 3 Year Growth 6.141937 Cash Ratio 3 Year Average 1063.6491
Price to Cash Flow Ratio 10.446426 PEG Payback 6.1817
PEG Ratio 1.0304 PE Ratio 93.873016
PE Ratio 10 Year Average 40.841012 PE Ratio 10 Year Growth 0.213414
PE Ratio 10 Year High 263.458333 PE Ratio 10 Year Low 11.715168
PE Ratio 1 Year Avg 31.379297 PE Ratio 1 Year High 101.730159
PE Ratio 1 Year Low 11.715168 PE Ratio 3 Year Avg 57.819454
PE Ratio 5 Year Avg 53.608144 PE Ratio 5 Year High 263.458333
PE Ratio 5 Year Low 11.715168 Free Cash Flow Ratio 10 Year Growth -0.007171
Free Cash Flow Ratio 3 Year Avg 19.263685 Price Change 1 Month 1.005782
Price to Cash Ratio 7.303541 Price / EBITDA 14.308003
Price to Sales Ratio 3.561542 Price to Sales Ratio 10 Year Growth 0.042207
Price to Sales Ratio 3 Year Avg 4.141333 Price to Sales Ratio 5 Year Avg 53.608144
Sale per Share 16.6052 Sales Yield 0.2808
Sustainable Growth Rate -0.0507 Tangible Book Value per Share -15.1178
Tangible Book Value per Share 3 year Avg 4.0915 Tangible Book Value per Share 5 year Avg 4.1323
Total Asset per Share 57.1377 Total Yield 0.085
Working Capital per Share 5.5779 Working Capital per Share 3 Year Avg 6.6567
Working Capital per Share 5 Year Avg 5.1943 Beta 0.557098
Company Profile

Bristol-Myers Squibb Company, a global biopharmaceutical company, engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical need, such as affective (psychiatric) disorders, Alzheimer?s/dementia, cardiovascular (primarily atherosclerosis/thrombosis), diabetes, hepatitis, HIV/AIDS, obesity, oncology, rheumatoid arthritis and related diseases, and solid organ transplant. Its products include PLAVIX for protection against fatal or non-fatal heart attack or stroke, and AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy; REYATAZ and SUSTIVA Franchise for the treatment of HIV, and BARACLUDE for the treatment of chronic hepatitis B infection; ERBITUX, SPRYCEL, and IXEMPRA for treating oncology related diseases; ABILIFY, a medicine for the treatment of mental illness; ORENCIA, a medicine for rheumatoid arthritis; and ONGLYZA for the treatment of type 2 diabetes. The company also has a pipeline with compounds in phase III clinical trials, including apixaban, belatacept, brivanib, dapagliflozin, ipilimumab, necitumumab, and XL-184. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. Bristol-Myers Squibb Company has various alliances and collaborations with sanofi-aventis; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Gilead Sciences, Inc.; AstraZeneca PLC; Pfizer Inc.; Exelixis, Inc.; ZymoGenetics, Inc.; and Alder Biopharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.